SAN DIEGO, March 26, 2020 /PRNewswire/ -- Biocept,
Inc. (Nasdaq: BIOC), a leading commercial provider of liquid
biopsy tests designed to provide physicians with clinically
actionable information to improve the outcomes of patients
diagnosed with cancer, announces that it has entered into an
agreement with a second California-based independent physician
association (IPA) to provide its Target Selector™ liquid biopsy
assay services to physicians and patients in their
network. Biocept's Target Selector™ offering includes the
choice of individual biomarker tests or a larger liquid biopsy
panel, enabling physicians to select the best approach for each
patient.
"We are pleased to reach an agreement with a second large
California-based IPA, this one in
the southern part of the state, to provide liquid biopsy services
for patients diagnosed with cancer," said Michael Nall, Biocept's President and CEO. "Our
offerings provide evidence-based, clinically actionable results in
a timely and cost-effective manner. This approach has been
resonating with IPAs, ACOs, HMOs and other value-oriented
stakeholders alike, and we look forward to further expanding our
reach within our home state of California."
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its
proprietary liquid biopsy technology to provide physicians with
information for treating and monitoring patients diagnosed with
cancer. The Company's patented Target Selector™ liquid biopsy
technology platform captures and analyzes tumor-associated
molecular markers in both circulating tumor cells (CTCs) and in
plasma (ctDNA). With thousands of tests performed, the platform has
demonstrated the ability to identify cancer mutations and
alterations to inform physicians about a patient's disease and
therapeutic options. For additional information, please
visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including
without limitation statements as to our ability to improve the
outcomes of patients diagnosed with cancer and the expansion in the
number of patients that will have an opportunity to benefit from
our liquid biopsy testing platforms, such statements are
forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. Readers are advised to review
our filings with the SEC, which can be accessed over the Internet
at the SEC's website located at http://www.sec.gov.
Contact:
LHA Investor Relations
Jody Cain
Jcain@lhai.com
310-691-7100
Media:
CORE IR:
Jules Abraham
julesa@coreir.com
917-885-7378
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocept-enters-into-laboratory-services-agreement-with-second-california-based-independent-physician-association-301030077.html
SOURCE Biocept, Inc.